New drug combo could shrink tumors and reduce radiation side effects in nose cancer

NCT ID NCT05941741

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding an immunotherapy drug (cadonilimab) and low-dose radiation to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 380 participants will be randomly assigned to receive either the new combination or standard treatment. The study measures how long patients live without the cancer coming back, overall survival, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cadonilimab (an immune checkpoint inhibitor)
What this could lead to: If successful, this could offer a more effective and less toxic treatment option for people with advanced nasopharyngeal cancer, potentially improving survival and quality of life.
What could go wrong: This is an early-phase trial with 380 participants, so results may not apply to everyone. Adding immunotherapy can cause immune-related side effects, and the low-dose radiation might not be as effective as standard doses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY IMMUNE CHECKPOINT INHIBITOR NASOPHARYNGEAL CARCINOMA RADIOTHERAPY

Contacts and locations

Locations

Cancer Center, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, China
Jiangxi Cancer Hospital
NOT_YET_RECRUITING

Nanchang, Jiangxi, China
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITING

Nanning, Guangxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.